



National  
Comprehensive  
Cancer  
Network®

**NCCN Clinical Practice Guidelines in Oncology™**

# **Cancer-Related Fatigue**

V.1.2008

**Continue**

[www.nccn.org](http://www.nccn.org)

## NCCN Cancer-Related Fatigue Panel Members

Ann M. Berger, PhD, RN, AOCN #  
UNMC Eppley Cancer Center at  
The Nebraska Medical Center

Amy Pickar Abernethy, MD †  
Duke Comprehensive Cancer Center

Ashley Atkinson, RN, MSN, OCN #  
University of Alabama at Birmingham  
Comprehensive Cancer Center

Andrea M. Barsevick, DNSc, RN, AOCN #  
Fox Chase Cancer Center

David Cella, PhD θ  
Robert H. Lurie Comprehensive Cancer  
Center of Northwestern University

Bernadine Cimprich, PhD, RN #  
University of Michigan  
Comprehensive Cancer Center

Charles Cleeland, PhD θ  
The University of Texas  
M. D. Anderson Cancer Center

Mario A. Eisenberger, MD † ω  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

Carmen P. Escalante, MD ϐ  
The University of Texas  
M. D. Anderson Cancer Center

Pamela Hinds, PhD, RN #  
St. Jude Children's Research Hospital/  
University of Tennessee Cancer Institute

Paul B. Jacobsen, PhD θ  
H. Lee Moffitt Cancer Center &  
Research Institute

Phyllis Kaldor, RN, MS, OCN #  
Arthur G. James Cancer Hospital and  
Richard J. Solove Research Institute at  
The Ohio State University

Matthew J. Loscalzo, MSW £  
City of Hope

Barbara A. Murphy, MD † £  
Vanderbilt-Ingram Cancer Institute

Tracey O'Connor, MD †  
Roswell Park Cancer Institute

William F. Pirl, MD, θ  
Dana-Farber/Brigham and Women's Cancer Center |  
Massachusetts General Hospital Cancer Center

Hope S. Rugo, MD † ‡ ξ  
UCSF Helen Diller Family  
Comprehensive Cancer Center

Paul Sabbatini, MD † ϐ  
Memorial Sloan-Kettering  
Cancer Center

F. Marc Stewart, MD †  
Fred Hutchinson Cancer Research Center/  
Seattle Cancer Care Alliance

Lynne I. Wagner, PhD θ  
Robert H. Lurie Comprehensive  
Cancer Center of Northwestern University

# Nursing

† Medical oncology

θ Psychiatry, psychology, including health behavior

ω Urology

£ Supportive care including palliative, pain management,  
pastoral care and oncology social work

‡ Hematology/Hematology oncology

ξ Bone marrow transplantation

ϐ Internal medicine

\* Writing Committee Member

**Continue**

## Table of Contents

[NCCN Cancer-Related Fatigue Panel Members](#)

[Summary of Guidelines Updates](#)

[Definition of Cancer-Related Fatigue \(FT-1\)](#)

[Standards of Care for Cancer-Related Fatigue in Children/Adolescents and Adults \(FT-2\)](#)

[Screening for Cancer-Related Fatigue \(FT-3\)](#)

[Primary Evaluation \(FT-4\)](#)

[Interventions for Active Treatment \(FT-5\)](#)

[Interventions for Long-Term Follow-up \(FT-6\)](#)

[Interventions for End of Life \(FT-7\)](#)

[Guidelines Index](#)

[Print the Cancer-Related Fatigue Guideline](#)

**For help using these documents, please click here**

[Manuscript](#)

[References](#)

This manuscript is being updated to correspond with the newly updated algorithm.

**Clinical Trials:** The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN member institutions, [click here: nccn.org/clinical\\_trials/physician.html](#)

**NCCN Categories of Evidence and Consensus:** All recommendations are Category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#)

These guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2008.

## Summary of the Guidelines Updates (1 of 2)

Summary of major changes in the 1.2008 version of the Cancer-Related Fatigue guidelines from the 4.2007 version include:

### (FT-1)

- The definition was changed to “Cancer-related fatigue is a distressing persistent, subjective sense of *physical, emotional and/or cognitive* tiredness...”

### (FT-2)

- A new first bullet was added that states: “Fatigue is rarely an isolated symptom and most commonly occurs with other symptoms, such as pain, distress, anemia, and sleep disturbances, in symptom clusters. Therefore, patients should be screened for multiple symptoms that may vary according to diagnosis, treatment, and stage of disease.”
- Fifth bullet: Changed to “...at all stages of disease, *prior to*, during and following treatment.”
- Eighth bullet: Changed to “...best accomplished by interdisciplinary *teams who are able to tailor interventions to the needs of the individual patient.*”

### (FT-3)

- First column: The panel included age specifications for each of the screening recommendations.
- Second column: The panel specified the severity score of “None to mild”, “moderate”, or “severe” by age.
- Third column: “Education plus common strategies...” was changed to “Education plus *general* strategies...”
- Footnote “c” is new to the page.

### (FT-4)

- Focused history:
  - ▶ The panel added “Prescription/OTCs and supplements”.
  - ▶ Third bullet: “In-depth fatigue assessment” was changed to “In-depth fatigue *history*”.
- Assessment of treatable contributing factors:
  - ▶ Fourth bullet: After sleep disturbance, the panel provided examples such as “obstructive sleep apnea, restless leg syndrome, narcolepsy, and insomnia.”

[Continued on next page](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## Summary of the Guidelines Updates (2 of 2)

Summary of major changes in the 1.2008 version of the Cancer-Related Fatigue guidelines from the 4.2007 version include:

### (FT-5)

- First column: “Daily self-monitoring of fatigue levels” was changed to “Self-monitoring of fatigue levels” and moved from the first column to the first bullet in the second column.
- Second column:
  - ▶ “Energy conservation; Seventh arrow under ”: “Naps that to not interrupt night-time sleep” was changed to “Limit naps to 45 minutes or less so as to not interfere with night-time sleep quality” (Also for [FT-6](#) and [FT-7](#))
  - ▶ Third bullet: “Distraction” changed to “Use distraction”.
- Third column, Nonpharmacologic: (Also for [FT-6](#) and [FT-7](#))
  - ▶ Activity enhancement:
    - ◊ Third arrow: Changed to include occupational therapy.
    - ◊ Fourth arrow: Added new bullet “Limitations secondary to metastases or other illnesses”. (For [FT-5](#) only)
  - ▶ Psychosocial Interventions: A new bullet was added, “Cognitive and behavioral therapy”. (Also for [FT-6](#) and [FT-7](#))
  - ▶ Sleep therapy: The panel deleted “Optimize sleep quality” and replaced with “Sleep restriction, Sleep hygiene, and Stimulus control”
  - ▶ The panel deleted “Family interaction”
- Fourth column: The panel deleted “Consider methylphenidate” as a separate recommendation, however, after “Consider psychostimulants”, the panel included as examples “methylphenidate or modafanil” with a cautionary footnote “h” regarding pharmacological interventions as well as mentioning that optimal dosing and schedules are not established.
- Footnote “e” regarding discussion of differences between Active treatment, Long term follow-up, and End-of-life treatment is new to the page.
- Footnote “f” regarding interventions being culturally specific and tailored to the individual needs of the patient is new to the page.

### (FT-6)

- First column: “Regular self-monitoring of fatigue” was changed to “Self-monitoring of fatigue”.
- Footnote “i” regarding adjustment of current treatment as well as consideration of nonpharmacologic management is new to the page.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## DEFINITION OF CANCER-RELATED FATIGUE

**Cancer-related fatigue is a distressing persistent, subjective sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning.**

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.


STANDARDS OF CARE IN CHILDREN/ADOLESCENTS AND ADULT  
CANCER-RELATED FATIGUE MANAGEMENT

- Fatigue is rarely an isolated symptom and most commonly occurs with other symptoms, such as pain, distress, anemia, and sleep disturbances, in symptom clusters. Therefore, patients should be screened for multiple symptoms that may vary according to diagnosis, treatment, and stage of disease.
- Fatigue is a subjective experience that should be systematically assessed using patient self-reports and other sources of data.
- Fatigue should be screened, assessed, and managed according to clinical practice guidelines.
- All patients should be screened for fatigue at their initial visit, at regular intervals during and following cancer treatment, and as clinically indicated.
- Fatigue should be recognized, evaluated, monitored, documented, and treated promptly for all age groups, at all stages of disease, prior to, during and following treatment.
- Patients and families should be informed that management of fatigue is an integral part of total health care.
- Health care professionals experienced in fatigue evaluation and management should be available for consultation in a timely manner.
- Implementation of guidelines for fatigue management is best accomplished by interdisciplinary teams who are able to tailor interventions to the needs of the individual patient.
- Educational and training programs should be implemented to ensure that health care professionals have knowledge and skills in the assessment and management of fatigue.
- Cancer-related fatigue should be included in clinical health outcome studies.
- Quality of fatigue management should be included in institutional continuous quality improvement (CQI) projects.
- Medical care contracts should include reimbursement for the management of fatigue.
- Disability insurance should include coverage for the continuing effects of fatigue.
- Rehabilitation should begin with the cancer diagnosis.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

SCREENING



<sup>a</sup>Recommended screen: “How would you rate your fatigue on a scale of 0-10 over the past 7 days?”

<sup>b</sup>Fatigue scale for children is simplified: Use “tired” or “not tired” as screen for young children (age < 6 or 7 y).

<sup>c</sup>Butt, Z., Wagner, L.I., Beaumont, J.L., Paice, J.A., Peterman, A.H., Shevrin, D., Von Roenn, J. H., Carro, G., Straus, J.L., Muir, J.C., & Cella, D. (in press). Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. *Journal of Pain and Symptom Management*.

<sup>d</sup>See “Patient/Family Education and Counseling” and “General Strategies for Management of Fatigue” based on clinical status: [Active Treatment \(FT-5\)](#), [Long Term Follow-up \(FT-6\)](#), [End of Life \(FT-7\)](#).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



**PRIMARY EVALUATION FATIGUE SCORE: MODERATE OR SEVERE**

Age > 12 y (4-10), Age 7-12 y (3-5), or Age 5-6 y (Tired)


**PATIENT CLINICAL STATUS**

**Focused history**

- Disease status and treatment
  - Rule out recurrence or progression
  - Current medications/medication changes
  - Prescription/OTCs and supplements
- Review of systems
- In-depth fatigue history
  - Onset, pattern, duration
  - Change over time
  - Associated or alleviating factors
  - Interference with function

**Assessment of treatable contributing factors:**


- Pain
- Emotional distress
  - Depression
  - Anxiety
- Anemia
- Sleep disturbance (eg, obstructive sleep apnea, restless leg syndrome, narcolepsy, insomnia)
- Nutrition Assessment
  - Weight/caloric intake changes
  - Fluid electrolyte imbalance: sodium, potassium, calcium, magnesium
- Activity level
  - Decreased activity
  - Decreased physical fitness
- Comorbidities
  - Infection
  - Cardiac dysfunction
  - Pulmonary dysfunction
  - Renal dysfunction
  - Hepatic dysfunction
  - Neurologic dysfunction
  - Endocrine dysfunction (hypothyroidism, hypogonadism, adrenal insufficiency)



Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## INTERVENTIONS FOR PATIENTS ON ACTIVE TREATMENT<sup>e</sup>



<sup>e</sup>See manuscript for discussion of differences between Active treatment, Long term follow-up, and End-of-life treatment. ([See MS](#))

<sup>f</sup>Interventions should be culturally specific and tailored to the needs of patients and families because not all patients may be able to integrate these options due to variances in individual circumstances and resources. (Sahler, O J Z., Varni, JW, Fairclough, D L, Butler R W, et al. Problem-Solving Skills Training for Mothers of Children with Newly Diagnosed Cancer: A Randomized Trial. Journal of Developmental & Behavioral Pediatrics. 23(2):77-86, April 2002)

<sup>g</sup>Concern is with environment. Limit activity to environments where risk of infection is low.

<sup>h</sup>Pharmacological interventions remain investigational, but have been reported to improve symptoms of fatigue in some patients. There is more evidence for methylphenidate and less for modafinil. These agents should be used cautiously and should not be used until treatment and disease specific morbidities have been characterized or excluded. Optimal dosing and schedule have not been established for use of psychostimulants in cancer patients.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

INTERVENTIONS FOR PATIENTS ON LONG-TERM FOLLOW-UP<sup>e</sup>

SPECIFIC INTERVENTIONS

Patient/Family Education and Counseling

General Strategies for Management of Fatigue

Nonpharmacologic<sup>f</sup>

Pharmacologic<sup>i</sup>

Information about known pattern of fatigue during and following treatment

- Self-monitoring of fatigue levels

- Energy conservation
  - ▶ Set priorities
  - ▶ Pace
  - ▶ Delegate
  - ▶ Schedule activities at times of peak energy
  - ▶ Labor-saving devices
  - ▶ Postpone nonessential activities
  - ▶ Limit naps to 45 minutes or less so as to not interfere with nighttime sleep quality
  - ▶ Structured daily routine
  - ▶ Attend to one activity at a time
- Use distraction (eg, games, music, reading, socializing)

- Activity enhancement (category 1)
  - ▶ Maintain optimal level of activity
  - ▶ Consider initiation of exercise program
  - ▶ Consider referral to rehabilitation: physical therapy, occupational therapy, physical medicine
  - ▶ Caution:
    - \* Late effects of treatment (eg, cardiomyopathy)
- Psychosocial interventions (category 1)
  - ▶ Cognitive and behavioral therapy
  - ▶ Stress management
  - ▶ Relaxation
  - ▶ Support groups
- Attention-restoring therapy (eg, nature) ([See MS](#))
- Nutrition consultation
- Sleep therapy ([See MS](#))
  - ▶ Sleep restriction
  - ▶ Sleep hygiene
  - ▶ Stimulus control

- Consider psychostimulants<sup>h</sup> (methylphenidate or modafinil) after ruling out other causes of fatigue
- Treat for anemia as indicated ([See NCCN Cancer and Treatment-Related Anemia Guidelines](#))
- Consider sleep medication

Repeat evaluation  
[See \(FT-4\)](#)

<sup>e</sup>See manuscript for discussion of differences between Active treatment, Long term follow-up, and End-of-life treatment. ([See MS](#))

<sup>f</sup>Interventions should be culturally specific and tailored to the patients and families because not all patients may be able to integrate these options due to variances in individual circumstances and resources. (Sahler, O J Z., Varni, JW, Fairclough, D L, Butler R W, et al. Problem-Solving Skills Training for Mothers of Children with Newly Diagnosed Cancer: A Randomized Trial. *Journal of Developmental & Behavioral Pediatrics*. 23(2):77-86, April 2002)

<sup>h</sup>Pharmacological interventions remain investigational, but have been reported to improve symptoms of fatigue in some patients. There is more evidence for methylphenidate and less for modafinil. These agents should be used cautiously and should not be used until treatment and disease specific morbidities have been characterized or excluded. Optimal dosing and schedule have not been established for use of psychostimulants in cancer patients.

<sup>i</sup>Adjustment of current treatments for pain, sleep disturbances, other symptoms and comorbidities, including drugs, etc. Nonpharmacologic management of pain may be considered such as palliative radiation, nerve blocks or epidural management.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

INTERVENTIONS FOR PATIENTS AT THE END OF LIFE<sup>e,j</sup>

SPECIFIC INTERVENTIONS

Patient/Family Education and Counseling

General Strategies for Management of Fatigue

Nonpharmacologic<sup>f,i</sup>

Pharmacologic

Information about known pattern of fatigue during and following treatment

- Expected end-of-life symptom
- May vary in intensity



- Energy conservation
  - ▶ Set priorities
  - ▶ Pace
  - ▶ Delegate
  - ▶ Schedule activities at times of peak energy
  - ▶ Labor-saving and assistive devices
  - ▶ Eliminate nonessential activities
  - ▶ Limit naps to 45 minutes or less so as to not interfere with night-time sleep quality
  - ▶ Structured daily routine
  - ▶ Attend to one activity at a time
  - ▶ Conserve energy for valued activities
- Use distraction (eg, games, music, reading, socializing)



- Activity enhancement
  - ▶ Optimize level of activity
  - ▶ Consider referral to rehabilitation: physical therapy, occupational therapy, physical medicine
  - ▶ Caution:
    - \* Bone metastases
    - \* Immunosuppression/neutropenia<sup>g</sup>
    - \* Thrombocytopenia
    - \* Anemia
    - \* Fever
- Psychosocial interventions (category 1)
  - ▶ Cognitive and behavioral therapy
  - ▶ Stress management
  - ▶ Relaxation
  - ▶ Support groups
- Attention restoring therapy (eg, nature) ([See MS](#))
- Nutrition consultation
- Sleep therapy ([See MS](#))
  - ▶ Sleep restriction
  - ▶ Sleep hygiene
  - ▶ Stimulus control



- Consider psychostimulants<sup>h</sup> (methylphenidate or modafinil) after ruling out other causes of fatigue
  - ▶ Consider corticosteroids (prednisone or dexamethasone)
- Treat for anemia as indicated ([See NCCN Cancer and Treatment-Related Anemia Guidelines](#))
- Consider sleep medication

Repeat evaluation  
[See \(FT-4\)](#)

<sup>e</sup>See manuscript for discussion of differences between Active treatment, Long term follow-up, and End-of-life treatment. ([See MS](#))

<sup>f</sup>Interventions should be culturally specific and tailored to the needs of patients and families because not all patients may be able to integrate these options due to variances in individual circumstances and resources. (Sahler, O J Z., Varni, JW, Fairclough, D L, Butler R W, et al. Problem-Solving Skills Training for Mothers of Children with Newly Diagnosed Cancer: A Randomized Trial. Journal of Developmental & Behavioral Pediatrics. 23(2):77-86, April 2002)

<sup>g</sup>Concern is with environment. Limit activity to environments where risk of infection is low.

<sup>h</sup>Pharmacological interventions remain investigational, but have been reported to improve symptoms of fatigue in some patients. There is more evidence for methylphenidate and less for modafinil. These agents should be used cautiously and should not be used until treatment and disease specific morbidities have been characterized or excluded. Optimal dosing and schedule have not been established for use of psychostimulants in cancer patients.

<sup>j</sup>Also [see NCCN Palliative Care Guidelines](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**Manuscript** This manuscript is being updated to correspond with the newly updated algorithm. Last updated 02/29/07

### NCCN Categories of Consensus

**Category 1:** There is uniform NCCN consensus, based on high-level evidence, that the recommendation is appropriate.

**Category 2A:** There is uniform NCCN consensus, based on lower-level evidence including clinical experience, that the recommendation is appropriate.

**Category 2B:** There is nonuniform NCCN consensus (but no major disagreement), based on lower-level evidence including clinical experience, that the recommendation is appropriate.

**Category 3:** There is major NCCN disagreement that the recommendation is appropriate.

**All recommendations are category 2A unless otherwise noted.**

### Overview

Fatigue is a common symptom in patients with cancer and is nearly universal in those receiving cytotoxic chemotherapy, radiation therapy, bone marrow transplantation, or treatment with biological response modifiers.<sup>1-10</sup> The problem, which affects 70% to 100% of cancer patients, has been exacerbated by the increased use of fatigue-inducing multimodal treatments and dose-dense, dose-intense protocols.<sup>11</sup> In patients with metastatic disease, the prevalence of cancer-related fatigue exceeds 75%, and cancer survivors report that fatigue is a disruptive symptom months or even years after treatment ends.<sup>12-21</sup> The distinction between tiredness, fatigue, and exhaustion has not been made consistently, despite conceptual differences.<sup>22, 23</sup> Patients perceive fatigue to be the most distressing symptom associated with cancer and its treatment, more distressing even than

pain or nausea and vomiting, which, for most patients, can generally be managed by medications.<sup>24,25</sup>

Fatigue in cancer patients has been under-reported, under-diagnosed, and under-treated. Persistent cancer-related fatigue affects quality of life (QOL), as cancer patients become too tired to participate fully in the roles and activities that make life meaningful.<sup>15,26-28</sup> Health care professionals have been challenged in their efforts to help patients manage this distressful symptom and to remain as fully engaged in life as possible. Because of the successes in cancer treatment, health care professionals are now likely to see patients with prolonged states of fatigue related to the late effects of treatment. Disability-related issues are relevant and often challenging, especially for cancer patients who are cured of their malignancy but have continued fatigue. Despite biomedical literature documenting this entity, it is often difficult for patients with cancer-related fatigue to obtain or retain disability benefits from insurers. Health care professionals should advocate for patients who require disability benefits and educate insurers about this issue.

Despite the prevalence of cancer-related fatigue, the exact mechanisms involved in its pathophysiology are unknown. Proposed mechanisms include abnormal accumulation of muscle metabolites, production of cytokines, changes in neuromuscular function, abnormalities in adenosine triphosphate (ATP) synthesis, serotonin dysregulation, and vagal afferent activation.<sup>32</sup> Limited evidence supports these proposed mechanisms, and much of the research to date has focused on correlates of fatigue.

To address the important problem of cancer-related fatigue, the NCCN convened a panel of experts. The NCCN Cancer-Related Fatigue Guideline, first published in 2000<sup>33</sup> and updated annually (see [www.nccn.org](http://www.nccn.org)),<sup>34</sup> synthesizes the available research and clinical experience in this field as well as provides recommendations for patient care.

## Defining Cancer-Related Fatigue

The panel defines cancer-related fatigue as a distressing, persistent, subjective sense of tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning. Compared with the fatigue experienced by healthy individuals, cancer-related fatigue is more severe, more distressing,<sup>12,35</sup> and less likely to be relieved by rest.<sup>36</sup> In terms of the defining characteristics, it is important to note the subjective sense of tiredness reported by the patient. As with pain, the clinician must rely on patients' descriptions of their fatigue and accompanying distress. Fatigue that interferes with usual functioning is another substantial component of the definition for cancer-related fatigue and the source of much distress for patients.<sup>8,37,38</sup> Investigations have documented a significant effect of fatigue on physical functioning during cancer treatment, and it is uncertain whether patients regain full functioning when treatment is over.<sup>39,40</sup>

## Standards of Care for Assessment and Management

The panel developed Standards of Care for Cancer-Related Fatigue Management, using the [NCCN Cancer Pain Guideline](#) and the [NCCN Distress Management Guideline](#) as exemplar models. These fatigue standards represent the best level of care for the assessment and management of fatigue in cancer patients, including children, adolescents and adults, and should provide guidance for health care professionals as they implement the guideline in their respective institutions and clinical settings. The overall goal of the standards and guideline is to ensure that all cancer patients with fatigue are identified as well as treated promptly and effectively.

The first standard recognizes fatigue as a subjective experience that should be systematically assessed using patient self-reports and other sources of data. Because it is a symptom that is perceived by the patient, fatigue can be described most accurately by self-report. The

history and physical examination, laboratory data, and descriptions of patient behavior by family members, especially in children, are important sources of additional information.

Fatigue should be screened, assessed, and managed for most patients according to clinical practice guideline. This guideline provides “best care” information based on current evidence to support treatment.<sup>41</sup> Patients should be screened for fatigue at their initial clinical visit, at appropriate intervals during and/or following cancer treatment, and as clinically indicated. Screening should identify the presence and severity of fatigue. Patients may be hesitant to initiate a discussion of their fatigue, so the responsibility for initiating screening must reside with the members of the primary oncology team.

Fatigue should be recognized, evaluated, monitored, documented, and treated promptly for all age groups at all stages of the disease, both during and after treatment. Implementation of this standard will ensure that fatigue is not overlooked or untreated in any patients.

Patients and families should be informed that managing fatigue is an integral part of total health care. All patients should receive symptom management. Furthermore, if patients cannot tolerate their cancer treatment or if they must choose between treatment and QOL, control of their disease may be diminished.<sup>42</sup>

Health care professionals experienced in fatigue evaluation and management should be available for consultation in a timely manner. Implementation of the guideline for fatigue is best managed by an interdisciplinary institutional committee, including medicine, nursing, social work, physical therapy, and nutrition.<sup>43</sup> The panel recognizes that education and training programs are needed to prepare experts in fatigue management, so that oncology health care professionals are knowledgeable and skilled in assessing and managing fatigue. These educational programs are now being offered, but much more attention

to these programs within institutional settings is necessary if professionals are to become skilled in managing fatigue.

Cancer-related fatigue should be included in clinical health outcome studies, and the NCCN Panel recommends that assessment of fatigue levels be included in outcomes research. Quality of fatigue management should be included in institutional continuous quality improvement (CQI) projects. Institutions can make faster progress in implementing the guidelines if they monitor adherence and progress with the guidelines. Medical care contracts should include reimbursement for the management of fatigue whether the patient needs referral to a physical therapist, dietitian, or the institution's symptom management service. In addition, disability insurance should include coverage for the continuing effects of fatigue that lead to persistent disability. Rehabilitation should begin with a cancer diagnosis and should continue even after cancer treatment ends.

### Guidelines for Evaluation and Treatment

The general schema of the fatigue algorithm incorporates the following phases: screening, primary evaluation, intervention, and re-evaluation. During the first phase, the health care professional must screen for fatigue, determine its presence or absence, and assess its intensity level. If the intensity level is moderate to severe, the health care professional is directed to conduct a more focused history and physical examination during the primary evaluation phase of the algorithm. This phase includes an in-depth fatigue assessment and an evaluation of contributing factors (eg, pain, emotional distress, anemia, altered nutritional status, sleep disturbance, decreased activity, comorbidities) that are frequently associated with fatigue and can be treated as an initial step in managing fatigue. If, however, a patient either does not have one of these treatable contributing factors or continues to have moderate-to-severe fatigue after treatment of the factors, the health

care professional should recommend additional treatment based on the NCCN fatigue guidelines.

After the evaluation phase, the guideline delineates a set of interventions for the amelioration of fatigue based on the patient's clinical status (ie, active cancer treatment, long-term follow-up, or end of life). Education and counseling are believed to be central to the effective management of fatigue. Additional interventions are nonpharmacologic and pharmacologic; however, in many instances a combination of approaches must be used. Finally, the algorithm calls for re-evaluation, leading to an iterative loop in fatigue screening and management.

### Screening

The first phase of the algorithm emphasizes screening of every patient for the presence or absence of fatigue. If fatigue is present, a quantitative or semiquantitative assessment should be performed and documented. For example, on a 0 to 10 numeric rating scale (zero = no fatigue and 10 = worst fatigue imaginable), mild fatigue is indicated as a score of 1 to 3, moderate fatigue as 4 to 6, and severe fatigue as 7 to 10.<sup>44,45</sup> The fatigue scale for children is simplified; thus, young children (age < 6 or 7 years) may be asked if they are "tired" or "not tired." Valid and reliable instruments are available to measure fatigue in children and adolescents.<sup>9,46-48</sup> If the screening process determines that fatigue is absent or at a mild level, the patient and family should receive education about fatigue and common strategies for managing it. Periodic re-screening and re-evaluation are recommended; for inpatients this should be carried out daily and for outpatients at subsequent routine and follow-up visits. It should be emphasized that survivors or patients who have been taken off treatment must still be monitored for fatigue, because fatigue may exist beyond the period of active treatment.<sup>12,13,49</sup>

Currently, screening is not systematic or effective in many practice settings for various reasons, which often include patient or family barriers and clinician barriers.<sup>50</sup> For example, patients may not want to bother their health care professional in the clinic or office or when they are hospitalized. Patients are also concerned that if they report high levels of fatigue, they might have their treatment altered. Also, patients do not want to be perceived as complaining and, therefore, may not mention fatigue. Or, they may assume that they just have to live with fatigue, because they believe there is no treatment for it. Health care professionals may not initiate a discussion about fatigue for many of the same reasons. First, clinicians may not recognize that fatigue is a problem for the patient. Fatigue, as a symptom, has been unrecognized and untreated. Conversely, medical advances have led to better control over the more noticeable or less-subtle acute symptoms of nausea, vomiting, and pain. Researchers have begun to document not only the prevalence and incidence of fatigue but also how it significantly disrupts a patient's QOL.<sup>51-53</sup> Second, health care professionals probably do not mention fatigue, because they may not be aware that there are effective treatments for fatigue. In addition, health care professionals strive to understand and explain the underlying pathophysiology and mechanisms of medical conditions; however, these processes have not been elucidated for fatigue.

Given these barriers, screening for cancer-related fatigue must be emphasized. Clinical experience with fatigue assessment has shown that some patients cannot put a numeric value on their fatigue. Consequently, some patients may need to rate fatigue as mild, moderate, or severe. In addition, in some circumstances, other sources of data must be used. For example, the patient may not be aware that fatigue has negatively affected his or her life; however, the spouse, parents, or other family members may be more cognizant of these changes and the effect of fatigue. An appendix to this manuscript

provides additional information and resources to assist in the selection of instruments to measure cancer-related fatigue.

Using the numeric rating scale (ie, 0 to 10 scale), fatigue studies in cancer patients have revealed a marked decrease in physical functioning at the level of 7 or higher.<sup>44,54</sup> The authors of an international study on fatigue in breast and prostate cancer patients evaluated and compared fatigue-intensity levels with scores from the MOS-SF-36 Physical Functioning Subscale.<sup>45</sup> The study documented a dramatic decrease in physical functioning when fatigue intensity levels were at level 7 (on a 0 to 10 scale). Based on these validated levels of intensity, the panel believes that this rating scale can be used as a guide in practice settings and decision-making.

#### **Primary Evaluation Phase [Fatigue Score: moderate-to-severe (4-10)]**

##### ***Focused History and Physical Examination***

When fatigue is rated as moderate to severe, with a score 4-10, a more focused history and physical examination should be conducted as part of the primary evaluation phase. A component of this evaluation is an assessment of the patient's current disease status, the type and length of treatment as well as its capacity to induce fatigue, and the patient's response to treatment. If possible, it should be determined whether the fatigue is related to a recurrence of malignancy for those patients assumed to be disease-free or related to a progression of malignancy for those patients with underlying disease. This is often an important factor causing patients with fatigue to seek further evaluation. If the fatigue is determined not to be related to disease recurrence, informing patients and family members will substantially reduce their anxiety levels.

Review of current medications (including over-the-counter, herbal, vitamins, and other supplements) is essential. In addition, recent medication changes should be noted. Medications and medication



interactions may contribute to worsening of fatigue. For example, certain cardiac medications (such as beta-blockers) may elicit bradycardia and subsequent fatigue. Combinations of different classes of medications (such as narcotics, antidepressants, antiemetics, and antihistamines) may contribute to excessive drowsiness and increasing fatigue. It may be appropriate to delete or adjust the dose of medications to treat fatigue. In some cases, altering either the dosage or dosing interval of a medication may subsequently improve fatigue.

A review of systems should be completed. This review may be helpful in determining the various organ systems affected and in directing the physical evaluation and diagnostic workup. Another component of the focused history is an in-depth fatigue assessment<sup>55</sup> that includes evaluation of aspects of fatigue onset, pattern, duration, change over time, associated or alleviating factors, and interference with function. Physical, emotional, and cognitive symptoms may be associated with fatigue. The health care professional must evaluate fatigue's effect on normal functioning and its effect on the patient's daily living or enjoyable activities. Because fatigue is a subjective condition involving a combination of symptoms and is experienced and reported differently by each person, it is important that the in-depth assessment should also include the patient's self assessment of the causes of fatigue.

#### **Assessment of Treatable Contributing Factors**

As part of this focused evaluation, the panel identified seven factors that are often causative elements in the fatigue experience and, therefore, should be specifically assessed. These factors include pain, emotional distress, sleep disturbance, anemia, nutrition, activity level, and other comorbidities.

Appropriate assessment of pain along with emotional distress and institution of effective treatment are essential. Descriptive studies have shown that, in adults as well as in children, fatigue seldom occurs by

itself and that it more commonly clusters with sleep disturbance, emotional distress (eg, depression, anxiety), or pain.<sup>8,56-59</sup>

Fatigue and depression have been documented as concurrent symptoms in cancer patients. In 987 lung cancer patients, Hopwood and Stephens<sup>60</sup> documented depression in 33% and that fatigue was an independent predictor of depression in this group. Newell and colleagues<sup>61</sup> found fatigue was the most commonly experienced and debilitating physical symptom for 201 oncology patients; about 25% of these patients also experienced depression. In 457 patients with Hodgkin's disease, Loge and colleagues<sup>62</sup> found that 26% had fatigue for 6 months or longer (defined as fatigue "cases") and that fatigue correlated moderately with depression ( $r = .41$ ). Fatigue cases had higher levels of depression than non-cases. Visser and Smets<sup>63</sup> studied the relationship between fatigue and depression in 308 adults in Amsterdam who were treated as outpatients with radiation therapy for cure or control of cancer. They concluded that fatigue and depression were independent conditions with different patterns over time: fatigue increased over the course of treatment but depression decreased. Fatigue was not predictive of depression, and depression did not predict fatigue in this sample.

Sleep disturbances are a neglected problem in oncology<sup>64</sup> and may range from hypersomnia to insomnia.<sup>65,66</sup> Sleep disturbances are prevalent in 30% to 75% of patients with cancer.<sup>67</sup> Several studies have shown that fatigued cancer patients in active treatment spend increased time resting and sleeping but that their pattern of sleep is often severely disrupted.<sup>68,69</sup> When sleep disturbances are present, the patient should be assessed for depression, because this is a common manifestation.<sup>70</sup> Patients may benefit from evaluation and education to improve sleep quality. In addition, sleep apnea can develop as a consequence of cancer treatment in the settings of surgery affecting the upper airway, changes in body composition, and alterations in hormone

status (ie, thyroid, estrogen, testosterone), therefore, obstructive sleep apnea should also be evaluated.

Studies have shown fatigue's association with anemia in cancer patients and its amelioration with erythropoietin (see section on "Treatment of Anemia-Related Fatigue with Erythropoietin"). Patients should undergo a nutritional assessment to evaluate weight gain and loss, caloric intake changes, impediments to nutritional intake, and fluid and electrolyte imbalances. Weight and weight changes should be carefully noted. The health care provider should also review and discuss changes in caloric intake with the patient. If there are substantial abnormalities, a consultation with a nutrition expert may be appropriate. Often fatigue symptoms can be improved by improving dietary intake, with appropriate caloric exchanges. Careful assessment of fluid and electrolytes should be performed. Imbalances in sodium, potassium, calcium, and magnesium serum levels are often reversible and, with appropriate supplementation, may improve fatigue. Nutritional intake may be affected by nausea, vomiting, loss of appetite, food disinterest, mucositis, odynophagia, bowel obstruction, diarrhea, and constipation.

Patients with moderate-to-severe fatigue should be queried about their activity level, including changes in exercise or activity patterns and the influence of deconditioning. This assessment is important when formulating a treatment plan that may include exercise. Can patients accomplish normal daily activities? Can they participate in formal or informal exercise programs? What is the amount and frequency of exercise? Has the patient modified exercise or other activity patterns since the development of fatigue? Exercise has been beneficial in lowering fatigue levels in certain populations of cancer patients.<sup>71-73</sup> However, before recommending an exercise program, the health care provider or exercise expert (eg, physiatrist, physical therapist) should assess the conditioning level of the patient. It is often difficult to

convince fatigued patients that exercise will improve their symptoms. It may be best to begin with discussions and low levels of activities, which gradually increase over a period of time. This is especially important if the patient is significantly deconditioned.

Non-cancer comorbidities may contribute substantially to symptoms of fatigue in the cancer patient. The status of each comorbidity must be reviewed in conjunction with the present treatment management of that comorbidity. If the comorbidity is not optimally managed, it may be necessary to further evaluate and improve that management. For example, if a patient has underlying congestive heart failure secondary to anthracycline cardiomyopathy and is experiencing symptoms of dyspnea and angina, fatigue may often be improved by stabilizing the condition and decreasing the frequency of episodes of congestive heart failure. This may entail introduction of new medications, titration of current medications, or both. It may also involve an invasive interventional assessment of the patient's cardiac status. Comorbidities that need review and assessment include infection as well as cardiac, pulmonary, renal, hepatic, neurologic, and endocrine dysfunction (including hypothyroidism, hypogonadism or adrenal insufficiency). Canaris and colleagues<sup>74</sup> noted the high incidence of thyroid dysfunction in normal individuals and in patients receiving thyroid medications; they suggested that more attention must be given to thyroid problems in both the general and cancer-patient populations. Development of hypothyroidism occurs after radiation therapy for Hodgkin's disease and other non-Hodgkin's lymphomas, head and neck cancers, and breast cancer, as well as after total body irradiation in bone marrow transplantation. Also, hypothyroidism has been noted in patients who have received interferon alfa-2b, aldesleukin (interleukin-2), L-asparaginase, and a multitude of combination chemotherapies. Hypogonadism is often seen in patients with advanced cancer. A recent cross-sectional pilot study by Strasser and colleagues<sup>75</sup> explored whether hypogonadism contributes to fatigue in

men with advanced cancer. The results of the study indicate that abnormally low levels of testosterone are associated with fatigue. However, additional research with larger samples is needed to clarify the incidence of hypogonadism and its association with specific malignancies and neurotoxic chemotherapy. The prevalence of hypogonadism may change with treatment and/or disease progression and, therefore, deserves further study.

#### **Patient Clinical Status**

After the primary fatigue evaluation is completed, the patient's clinical status (active cancer treatment, long-term follow-up with no active treatment except hormonal therapy, or end of life) should be determined, because it will influence cancer-related fatigue management and treatment strategies. However, some general treatment guidelines apply across all clinical categories.<sup>76</sup>

If any of the seven contributing factors (including pain, emotional distress, sleep disturbance, anemia, nutritional alterations, decrease in activity level, and comorbidities) known to be associated with cancer-related fatigue is identified during the primary evaluation phase, it should be treated as an initial approach to fatigue management. NCCN clinical practice guidelines are also available to guide the treatment of pain (see [NCCN Cancer Pain Guideline](#)), distress (see [NCCN Distress Management Guideline](#)), and anemia (see [NCCN Cancer and Treatment-Related Anemia Guideline](#)). Updated guidelines are available at [www.nccn.org](http://www.nccn.org). Treatment of sleep disturbances, nutritional alterations, and physical deconditioning are discussed under “Nonpharmacologic Interventions” for the three levels of clinical status.

### **Interventions for Patients on Active Treatment**

#### **Education and Counseling of Patient and Family**

Education about fatigue and its natural history should be offered to all cancer patients<sup>50</sup> but is particularly essential for patients beginning fatigue-inducing treatments. Optimally, Information about the usual

pattern and duration of fatigue should be given to patients and their families before the onset of fatigue. All patients should be informed that they might develop moderate-to-severe fatigue when they are undergoing therapy (such as radiation, chemotherapy, or biotherapy). Patients should also be informed that if fatigue does occur, it may be a consequence of the treatment and not necessarily an indication that the treatment is not working or that the disease is progressing. Daily self-monitoring of fatigue levels in a treatment log or diary can be helpful.

In addition to education, the panel recommends counseling for patients about general strategies useful in coping with fatigue. These include strategies such as energy conservation and distraction. Energy conservation encompasses a common sense approach that helps patients to prioritize and pace activities, and to delegate less essential activities.<sup>77</sup> Patients should be counseled that it is permissible to postpone all nonessential activities if they are experiencing moderate-to-severe fatigue. One useful plan is to maintain a daily and weekly diary that allows the patient to ascertain peak energy periods.<sup>78</sup> The fatigued patient can then plan activities accordingly. A multisite clinical trial of energy conservation in 296 patients receiving cancer treatment by Barsevick and colleagues<sup>79</sup> reported significantly lower fatigue in those receiving the experimental intervention. Some participants in descriptive studies have suggested that activities designed to distract (eg, games, music, reading, socializing) are helpful in decreasing fatigue, although the mechanism is unknown.<sup>80,81</sup>

#### **Nonpharmacologic Management**

Of the specific nonpharmacologic interventions during active cancer treatment, activity enhancement (category 1) and psychosocial interventions (category 1) have the strongest evidence base for treating fatigue; however, attention-restoring therapy, dietary management, and sleep therapy all have some evidence to support them.<sup>82</sup>

### *Activity Enhancement.*

In cancer patients, toxic treatments and a decreased level of activity during treatment are presumed to reduce physical performance. Therefore, patients must use greater effort and expend more energy to perform their usual activities, which leads to fatigue. Activity enhancement using physical exercise training programs, however, can decrease the loss in physical performance and increase functional capacity leading to a reduced effort and decreased fatigue.<sup>83</sup> Courneya and colleagues reported that aerobic exercise improved cardiopulmonary function and QOL in cancer survivors.<sup>84,85</sup> It is reasonable to encourage all patients to maintain as normal a level of activity as possible during cancer treatment. However, some patients, especially those with comorbidities or substantial deconditioning, should be referred to physical therapy or to physical medicine and rehabilitation as indicated for assessment and exercise prescription. Specific exercise programs should be preceded by a careful evaluation of comorbidities and exercise contraindications. The exercise program itself should be individualized using the patient's age and gender, the type of cancer present, the treatment the patient is receiving for cancer, and the patient's physical fitness level. The program should begin at a low level of intensity and duration, progress slowly, and be modified as the patient's condition changes. Any exercise program must be cautiously prescribed if patients have comorbidities, such as bone metastases, immunosuppression or neutropenia, low platelet counts or thrombocytopenia, anemia, fever, or other treatment complications. A safe and beneficial exercise program provides guidance related to the type of exercise and its intensity, duration, and frequency.<sup>86</sup> If the patient is neutropenic, activity should be limited to such environments in which the risk of infection is low (eg, public swimming pools are contraindicated).

Research about the effects of exercise on cancer-related fatigue includes studies of patients during treatment and studies of patients

who have completed treatment. These studies are rapidly increasing in number, because exercise for cancer patients is no longer a novel idea, and because the benefits of exercise as well as the safety have been demonstrated. A number of meta-analyses<sup>87-90</sup> and systematic reviews<sup>76,91-95</sup> have addressed exercise as an intervention for cancer patients in active treatment as well as those in long-term follow-up. The reviewed studies included supervised laboratory programs<sup>72,85,96</sup> and home-based programs.<sup>71,84,97</sup> The type of aerobic exercise has varied: there were some walking programs,<sup>71,84</sup> some exercise bicycling,<sup>72,98</sup> and studies in which patients were able to choose the kind of exercise they preferred.<sup>73,99</sup> In a recent clinical trial of men with prostate cancer receiving androgen deprivation therapy, resistive strength training was found to decrease fatigue and to increase muscle strength.<sup>100</sup> Some regimens were applied in laboratories and some were home-based regimens. The programs varied in length from 6 weeks for patients who were going through radiation therapy to 6 months for those in chemotherapy and the entire duration of bone marrow transplantation. The exercise interventions have varied somewhat but most include progressive programs of 20 to 30 minute sessions, three to five days a week, at an intensity equal to 60% to 80% of maximum heart rate (Rate of Perceived Exertion of 11 to 14). In one study, a dose-response pattern was observed with fatigue levels inversely related to three increasing levels of exercise.<sup>99</sup> However, patients who exercised more than 60 minutes per day were more likely to report higher levels of fatigue, suggesting a maximum effective dose for patients receiving adjuvant chemotherapy for breast cancer.

No serious adverse events were reported in any of the studies, although high-risk patients with serious comorbidities were excluded, and most exercise programs were flexible and symptom limited. All of these studies showed lower levels of fatigue and emotional distress as well as decreased sleep disturbance (if this was studied as an outcome) in patients who exercised during treatment compared to

controls or to baseline scores in single-group designs. Exercise has a powerful effect on cancer-related fatigue, and fatigue levels were 40% to 50% lower in exercising participants, even in studies with relatively small sample sizes. The evidence supporting exercise as an intervention for fatigue is category 1 based on the number of studies conducted, the good quality of the designs, the large effect size of exercise on cancer-related fatigue, and the consistent outcomes across studies. Some additional studies on the effects of exercise in patients receiving cancer treatment that have not looked specifically at fatigue as an outcome have, nevertheless, shown increases in functional capacity, lending support to the theory regarding the positive effects of exercise on decreasing fatigue.<sup>101,102</sup> Studies have also shown decreases in emotional distress and increased QOL in patients who engaged in exercise during cancer treatment.<sup>100,103</sup>

#### *Psychosocial Interventions.*

Patients should be counseled about stress management and methods for dealing with depression and anxiety, which are commonly associated with fatigue during cancer treatment.<sup>104</sup> Although a strong correlation exists between emotional distress and fatigue, the precise relationship is not clearly understood. Both depression and anxiety may be characterized by fatigue, but it is also evident that high levels of fatigue may cause emotional distress when valued roles and activities are affected. Preliminary evidence in a recent study suggests that the relationship between fatigue and depression in cancer patients is mediated by functional status<sup>105</sup>

Studies testing interventions to reduce stress and to increase psychosocial support in cancer patients have shown reductions in fatigue levels, usually measured as a component of mood state.<sup>106-111</sup> The interventions have included education,<sup>109-111</sup> support groups,<sup>107,108</sup> individual counseling,<sup>106,112</sup> a comprehensive coping strategy,<sup>113</sup> stress management training,<sup>114</sup> and a tailored behavioral intervention.<sup>39</sup> The

studies were randomized controlled trials, with good experimental designs and adequate sample sizes, and included various cancer populations; thus, the level of evidence for using psychosocial interventions to treat fatigue is category 1. However, in many of these studies, fatigue was a secondary endpoint measured by a single item or a subscale of an instrument to measure emotional distress.

#### *Attention-restoring Therapy.*

Attention-restoring therapy is another type of nonpharmacologic intervention. Attentional fatigue, which is an aspect of the sensory dimension of fatigue, has been defined as a decreased capacity to concentrate or to direct attention during stressful or demanding situations.<sup>115</sup> Cimprich developed and tested attention-restoring interventions in women with breast cancer.<sup>116-118</sup> Patients who received these interventions displayed improved concentration and problem solving on neurocognitive tests and returned earlier to work after surgery compared with control individuals.<sup>117</sup> When the intervention was begun before surgery, the experimental group showed greater preoperative to postoperative recovery of capacity to direct attention.<sup>116</sup> Bird watching and sitting in the park are examples of experiences in natural environments that have a restorative influence on cancer patients.

#### *Nutrition Consultation.*

Many cancer patients have changes in nutritional status. Because cancer and treatment can interfere with dietary intake, nutrition consultation may be helpful in managing the nutritional deficiencies that result from anorexia, diarrhea, nausea, and vomiting.<sup>119</sup> Adequate hydration and electrolyte balance are also essential in preventing and treating fatigue.

### *Sleep Therapy.*

Cancer patients report significant disturbances in sleep patterns. Both insomnia and hypersomnia are common, with disrupted sleep as a common denominator.<sup>64,67,120</sup> Nonpharmacological interventions identified for sleep therapy include cognitive-behavioral therapy (CBT) and complementary therapies. These interventions are designed to optimize sleep quality and may also decrease fatigue.<sup>121</sup>

The cognitive-behavioral interventions include relaxation training along with stimulus control, sleep restriction, and sleep hygiene. Stimulus control includes going to bed when sleepy, going to bed at approximately same time each night, and maintaining a regular rising time each day. Sleep restriction includes avoiding long or late afternoon naps and limiting time in bed. Sleep hygiene includes techniques to promote a good night's sleep and optimal functioning the next day, such as avoiding caffeine after noon and establishing an environment that is conducive to sleep (eg, dark, quiet, and comfortable). These strategies were employed in a pilot study with women during adjuvant breast cancer chemotherapy. Sleep/wake patterns remained consistent with normal values except for increased number and length of nighttime awakenings.<sup>122</sup> For children with cancer, a consistent bedtime and routine, a conducive environment, and presence of security objects (such as blankets and toys) are effective measures. A number of published studies<sup>123-126</sup> support the conclusion that cognitive-behavioral therapy interventions designed to optimize sleep quality may also improve fatigue.

Complementary therapies such as massage therapy,<sup>127,128,129</sup> yoga<sup>130-132</sup>, muscle relaxation,<sup>133,134</sup> and mindfulness-based stress reduction<sup>135-138</sup> have been evaluated in pilot studies; the preliminary data suggest that they may be effective in reduction of fatigue in cancer patients.

### *Pharmacologic Interventions*

The last type of cancer-related fatigue treatment is pharmacologic therapy. Aside from the well-established treatment of anemia with erythropoietin (see the [NCCN Cancer and Treatment-Related Anemia Guideline](#)), there have been few reports of systematic investigation of drugs to treat cancer-related fatigue, although there have been some clinical reports.<sup>139</sup> Studies on a selective serotonin reuptake inhibitor paroxetine showed no influence by this antidepressant on fatigue in patients receiving chemotherapy.<sup>140,141</sup> Antidepressant is no longer a recommended option.

Psychostimulants, such as methylphenidate, can be considered after ruling out other causes of fatigue. Psychostimulants have been found to reduce fatigue in other chronic conditions<sup>142,143</sup> and are now being evaluated in some studies on cancer patients to ameliorate opioid-induced somnolence. Most recently, a randomized, double-blind, placebo-controlled study with methylphenidate in cancer related fatigue showed that both placebo and methylphenidate improved fatigue, with no significant difference from placebo at one week.<sup>144</sup> Another phase III, randomized, placebo-controlled trial for dexmethylphenidate was conducted in adult cancer patients and significantly more effective improvement of fatigue than placebo was achieved for dexmethylphenidate.<sup>145</sup> The psychostimulant, modafinil, has been approved by the Food and Drug Administration for use in narcolepsy. A case report using modafinil showed improvements in daytime wakefulness and normalization of sleep-wake cycle<sup>146</sup> in 2 adult patients with advanced cancer; modafinil has been reported to be helpful in cancer-related fatigue,<sup>147</sup> but no studies have been published as yet. Therefore, the panel does not believe there is sufficient evidence at this time to recommend pharmacologic therapy for cancer patients who have moderate or severe fatigue and recommends that more research be done in this area.

### Interventions for Patients on Long-Term Follow-Up

More than 9 million U.S. people now living have a history of cancer. Of the approximately 1,399,790 persons in the United States who will be diagnosed with cancer in 2006, 65% are expected to survive at least 5 years.<sup>148</sup> These improvements in survival have led to efforts to enhance symptom management, QOL, and overall functioning of individuals entering long-term follow-up after cancer treatment. As previously mentioned, fatigue is an acute effect of cancer (or medical treatment), but fatigue can also be a long-term or late effect of disease or treatment.<sup>149,150</sup> Those disease-free individuals who are no longer receiving treatment may continue to report unusual fatigue for months or years after treatment cessation.<sup>12-14,16-21</sup> Researchers have suggested that such fatigue may be due to persistent activation of the immune system<sup>16,151</sup> or to other factors, such as late effects of treatment on major organ systems.<sup>151</sup> However, there are few longitudinal studies examining fatigue in long-term disease-free patients for its prevalence, correlates, duration, and underlying mechanisms. We have limited knowledge of fatigue in survivors.

Incidence and prevalence rates for fatigue in this population range from 17% to 21% when strict ICD-10 diagnostic criteria are applied<sup>152</sup> and range from 33% to 53% when other criteria (such as a score of 4 or more on the 0 to 10 fatigue scale) are used.<sup>153</sup> In contrast to these findings, Canadian and U.S. ovarian cancer survivors (n = 100), who were diagnosed a mean of 7.2 years before the survey, reported equivalent energy levels when compared with the general population.<sup>154</sup> As a consequence, what constitutes valid incidence and prevalence rates in disease-free patients requires more study.

In general, most research reports to date are limited by their cross-sectional designs,<sup>24,51,150,152,155-157</sup> lack of comparison groups,<sup>24,51,157</sup> heterogeneous samples,<sup>152,158</sup> use of differing fatigue scales, small sample sizes,<sup>151</sup> varying baseline survivorship definitions (ie, time

since diagnosis versus time since treatment cessation), and different mean survivorship durations (ie, from 12-18 months to 7 plus years). These design issues make it difficult to reach conclusions about the effect of fatigue's prevalence, incidence, duration, associated risk factors, and QOL. Additionally, most fatigue studies of post-treatment disease-free patients have been conducted in Caucasian, English-speaking breast cancer,<sup>16,151,155</sup> and peripheral stem cell or bone marrow transplant patients<sup>86,158</sup> with few exceptions.<sup>17,19,21</sup>

The cause of fatigue in post-treatment disease-free patients is unclear and probably multifactorial.<sup>159</sup> One cross-sectional comparative study investigated fatigue and physiologic biomarkers of immune system activation in 20 breast cancer survivors who were fatigued (a mean of 5 years since diagnosis) and in 20 non-fatigued survivors.<sup>151</sup> Fatigued survivors had significantly higher serum markers (interleukin-1 receptor antagonist [IL-1ra], soluble tumor necrosis factor type II [sTNF-RII], and neopterin) and lower cortisol levels when compared with non-fatigued survivors. Significantly higher numbers of circulating T lymphocytes that also correlated with elevated serum IL-1ra levels suggesting that persistent fatigue in survivors may be caused by a chronic inflammatory process involving the T-cell compartment.<sup>16</sup>

Other risk factors associated with fatigue in post-treatment disease-free patients include pretreatment fatigue, anxiety and depression levels,<sup>160</sup> physical level activities,<sup>161,162</sup> coping methods and cancer-related stressors, comorbidities,<sup>163</sup> type of malignancy, prior treatment patterns,<sup>157</sup> and treatment late effects.<sup>150</sup> For example, in one Norwegian study, a small proportion of long-term disease-free cancer patients who had pre-existing coronary artery disease had 30% higher fatigue levels compared with controls.<sup>163</sup> In another Norwegian study that investigated fatigue in Hodgkin's disease survivors in remission for more than 5 years, higher fatigue levels were documented in those who had pulmonary dysfunction.<sup>153</sup> In these survivors, the prevalence of

chronic fatigue was 2 to 3 times higher than in survivors who did not have such impairment. No significant correlations in this study were found between fatigue and cardiac sequelae as measured by echocardiography, exercise testing, and chest radiography.<sup>153</sup> Prior treatment patterns may affect the survivor's fatigue. For example, in a study of 322 post-treatment disease-free breast cancer patients, the highest fatigue scores occurred in women who had received previous combination therapy versus other forms of treatment.<sup>157</sup> Women who had received radiation therapy had the lowest fatigue scores. Two studies testing the effects of physical activity interventions on fatigue in breast cancer survivors found that individualized, prescriptive exercise reduced fatigue. However, researchers emphasize it is critical that exercise be individualized to the survivors abilities to prevent exacerbation of cancer treatment toxicities.<sup>161,162</sup>

#### ***Education and Counseling of Patient and Family***

Patients who are completing treatment and entering the phase of long-term follow-up and their families should be educated about the pattern and level of fatigue that can be expected during this period. Although a significant subset of patients continue to experience distressing levels of fatigue that interfere with function,<sup>12,13</sup> most patients experience a gradual decrease in fatigue and return of energy to normal levels.<sup>14,154</sup> Regular self-monitoring of fatigue levels is helpful to document the decrease of fatigue that normally occurs after treatment. Oncology care providers should continue to screen regularly for fatigue during follow-up visits.

#### ***Nonpharmacologic Management***

The specific interventions recommended to manage fatigue during active cancer treatment are also recommended for disease-free patients on long-term follow-up.<sup>76</sup> Activity enhancement is a category 1 recommendation. In fact, improving strength, energy, and fitness through regular exercise, even a moderate walking exercise program, has been shown to facilitate the transition from patient to survivor,

decrease anxiety and depression,<sup>164</sup> improve body image, and increase tolerance for physical activity.<sup>98</sup> However, if the patient is significantly deconditioned, weak, or may have relevant late effects of treatment (such as cardiopulmonary limitations), referral to a physiatrist or a supervised rehabilitation program may be indicated. Exercise should be recommended with caution in patients who have fever or remain anemic, neutropenic, or thrombocytopenic after treatment. Although exercise has the best evidence to support its effectiveness,<sup>76,89-95,165</sup> psychosocial interventions (category 1), energy conservation, distraction, attention-restoring therapy, sleep therapy,<sup>121,166</sup> family interaction, and nutritional therapy are all helpful in this population as well.

#### ***Pharmacologic Interventions***

Cause-specific pharmacologic therapy may include hypnotics as a possible short-term treatment for insomnia; If indicated, anemia should also be treated (see [NCCN Cancer and Treatment- Related Anemia Guideline](#)). Whether psychostimulants are useful for treating fatigue in disease-free patients on long-term follow-up has not been reported, although psychostimulants, such as methylphenidate, can be considered after ruling out other causes of fatigue.

#### ***Interventions for Patients at the End of Life***

Although the assessment and management of fatigue at the end of life parallels the general principles of this guideline, there are a few issues that are specific to this population. Factors that have a greater likelihood of association with fatigue at the end of life include anemia, medication adverse effects and polypharmacy, cognitive impairment, adverse effects of recent treatment, and malnutrition.<sup>167</sup> Evaluating and correcting these contributing factors could reduce fatigue severity.

At the end of life, most research has demonstrated that cancer patients experience fatigue in the context of multiple symptoms. In a study of



278 Swedish adults admitted to a palliative care unit, 100% reported fatigue; other symptoms included pain (83%), dyspnea (77%), and appetite loss (75%).<sup>168</sup> Among 58 Australian cancer patients receiving inpatient or home-based care, the most prevalent symptoms were weakness (87%), fatigue (84%), sleep during the day (75%), and pain (72%).<sup>169</sup> Walsh and Rybicki<sup>170</sup> cluster analyzed 25 symptoms in 1000 consecutive admissions to a palliative care program and found seven symptom clusters. The fatigue cluster included easy fatigue, weakness, anorexia, lack of energy, dry mouth, early satiety, weight loss, and taste changes. The report of multiple symptoms is not without consequences. Mystakidou and colleagues<sup>171</sup> reported that patient desire for a hastened death was predicted by feeling sad, lack of appetite, pain, and fatigue.

#### ***Education and Counseling of Patient and Family***

Individuals with advanced cancer and their caregivers need information about the management of symptoms, including fatigue,<sup>172</sup> with specific information related to the disease trajectory.<sup>173,174</sup> This includes information about the causes, patterns, and consequences of fatigue during treatment for advanced cancer and at the end of life. As noted in these NCCN guidelines, there are many causes of fatigue in this group, including disease progression, medications, sleep disturbances, pain, poor nutrition, depression, and anemia.

It is likely that fatigue will increase substantially as the disease progresses; however, patterns of fatigue are variable. For some adults, fatigue may be characterized as constant and unrelenting; for others, it is unpredictable and may come on suddenly.<sup>52,175</sup> In both adults and children, fatigue is likely to occur in the context of multiple symptoms. In a large sample of adults (N = 1000) receiving palliative care, Walsh and colleagues<sup>176</sup> noted that individuals with advanced cancer had multiple symptoms. Pain was the most prevalent (84% of patients), followed by easy fatigue (69%), weakness (66%), and lack of energy (61%).

Children with advanced cancer also experienced multiple symptoms at the end of life, most commonly fatigue, pain, and dyspnea.<sup>177</sup> There is also the possibility, suggested by Given and colleagues,<sup>37,178</sup> that pain and fatigue together could have a synergistic effect that worsens the overall symptom experience in elderly cancer patients.

Several major consequences of fatigue have been described, including its effect on functional status, emotional distress, and suffering. As fatigue escalates, it is likely to interfere increasingly with usual activities.<sup>175</sup> Families need to be apprised of this problem so they can begin planning for it. In addition, fatigue is likely to have increasing effect on emotional well-being.<sup>175,177</sup> According to parents who cared for a child at the end of life, more than 90% of the children experienced fatigue and almost 60% experienced a great deal of suffering from it.<sup>177</sup> In a case study of 15 adults with advanced disease, Krishnasamy found that fatigue resulted in substantial regret, sadness, and sense of loss due to the deterioration of one's health.<sup>175</sup>

Given the high prevalence of fatigue and other symptoms at the end of life, symptom management needs to be a major focus of care. Active commitment by the health care team to palliative care is critical when aggressive cancer therapy is given to those with a low likelihood of long-term survival.<sup>177</sup> Although there is no effective therapy for some causes of fatigue and other symptoms, treatment of those more amenable to therapy could help to relieve suffering.<sup>76</sup>

#### ***General Strategies for Management of Fatigue***

Energy conservation is a self-care strategy for individuals with advanced cancer and their caregivers.<sup>79</sup> Energy conservation is defined as the deliberately planned management of one's personal energy resources to prevent their depletion. The goal of energy conservation is to maintain as balance between rest and activity during times of high fatigue so that valued activities can be maintained. Energy conservation strategies include priority setting, delegating activities of lesser

importance, pacing oneself, taking extra rest periods, and planning high-energy activities at times of peak energy. It may also include the use of labor-saving devices (such as a bedside commode, walker, raised toilet seat, energy-saving appliances, and grabbing tools). In a situation of escalating fatigue at the end of life, family members may wish to designate individuals to assume activities relinquished by the individual with cancer.

### ***Nonpharmacologic Interventions***

Although fatigue may increase at end of life, individuals may choose to be active despite failing health. As noted earlier, exercise is effective in reducing fatigue during active treatment. There is also some evidence that exercise is beneficial to individuals with incurable cancer and short life expectancy. A group exercise program was pilot-tested in 63 Norwegian palliative care outpatients.<sup>179</sup> The program consisted of two 50-minute sessions twice a week for six weeks. A combination of strength building, standing balance, and aerobic exercise was used. The exercise participants had less physical fatigue and increased walking distance. There were no adverse effects of exercise although 46% of the 63 participants did not complete the program.

A small pilot study was conducted to evaluate an exercise program for nine individuals with advanced cancer enrolled in a home hospice program.<sup>180</sup> A physical therapist guided participants in the selection of several activities (such as walking, performing arm exercises with resistance, marching in place, and dancing). These were performed at different times throughout the day on a schedule devised jointly by the therapist and participant. All participants were able to increase their activity level over a 2-week period without increased fatigue. There was also a trend toward increased QOL and decreased anxiety. Although more research is needed, enhanced activity shows promise as a fatigue management strategy at the end of life. Psychosocial interventions

(category 1), attention-restoring therapy, sleep therapy, family interaction, and nutritional therapy are also helpful to this population.

A 12-week exercise program tested on 82 men with locally advanced or metastatic prostate cancer was compared to a wait-list control group (N = 73).<sup>100</sup> The men in the exercise group reported less interference of fatigue with daily activities and better quality of life. They also demonstrated better upper and lower body muscle fitness. Body composition was not affected.

Based on a systematic review of 20 exercise studies relevant to fatigue and muscle wasting in multiple myeloma, Strong<sup>181</sup> summarized weight-bearing precautions for bone metastases as well as exercise guidelines for adults with solid tumors and hematological cancers; older cancer survivors; and individuals with cancer-related fatigue. They also recommended an exercise protocol for multiple myeloma that incorporated aerobic, resistance, and flexibility exercises.

### ***Pharmacologic Interventions***

There continues to be interest in psycho-stimulant drugs although studies have had mixed results. Bruera et al<sup>182</sup> compared 52 palliative care outpatients who received methylphenidate (titrated up to 20 mg. per day for 7 days) with a placebo control group (N = 53). Fatigue intensity decreased in both groups; methylphenidate was not superior to placebo. Other studies of fatigued breast cancer survivors,<sup>183</sup> advanced cancer patients,<sup>184</sup> and HIV patients<sup>185</sup> support the use of this drug. Additional studies are needed.

In Sweden, the corticosteroid, betamethosone (a dexamethosone equivalent), has been widely used to treat fatigue in palliative care patients. In a survey, 40% of palliative care physicians reported using it to treat fatigue and 80% reported very good or some effect of the drug on fatigue.<sup>186</sup> Modafinil also shows some promise for cancer-related fatigue. Morrow et al<sup>187</sup> conducted an open label study of modafinil for

82 breast cancer survivors with persistent fatigue. The dose was 200 mg per day for one month. Eighty-three percent reported reduction of fatigue, 10% had no improvement, and 7% dropped out of the study. In a randomized pilot study of 16 adults with brain tumors, Kaleita and colleagues<sup>188</sup> titrated modafinil dose from 100 mg to 600 mg (optimal dose) for 13-17 days and concluded that modafinil was a safe and effective treatment for fatigue.

In addition to psycho-stimulants, the progestational agent, megestrol acetate (MA) has demonstrated dose-dependent improvement in fatigue as well as appetite and well being.<sup>182,189</sup> In fact, a study comparing MA with dexamethasone showed that MA had fewer side effects than dexamethasone.<sup>190</sup> The authors suggested that for planned long term use (weeks or months) MA might be preferable. A systematic review paper demonstrated the safety and efficacy of MA for cancer patients.<sup>191</sup>

Micronutrient deficiency could also be responsible for increased fatigue in advanced cancer patients. Carnitine is a micronutrient involved in the production of energy at the cellular level,<sup>192</sup> that has been shown to be deficient in people who are chronically ill. Advanced cancer patients are at risk for carnitine deficiency because of decreased intake and increased renal loss. L-carnitine supplementation has been examined in an open label Phase I/II study.<sup>193</sup> L-carnitine was given to 27 advanced cancer patients in escalating doses (250-3000 mg per day). Twenty-one individuals completed the study with 17 showing increases in carnitine levels. In a responder analysis, a dose-response relationship was observed for fatigue. Although this work is very preliminary, carnitine supplementation shows some promise for fatigue management.

### Re-Evaluation Phase

Because fatigue may arise at many points in the course of a patient's disease and treatment, ongoing re-evaluation of the patient's status (with appropriate modifications and institution of new treatments) is an integral part of effective, overall fatigue management.

### Summary

The NCCN Cancer-Related Fatigue Guidelines propose a treatment algorithm in which patients are evaluated regularly for fatigue using a brief screening instrument and are treated as indicated by their fatigue level. The algorithm's goal is to identify and treat all patients with fatigue that causes distress or interferes with their daily activities or functioning.

Management of fatigue begins with primary oncology team members who perform the initial screening and either provide basic education and counseling or expand the initial screening to a more focused evaluation for moderate or higher levels of fatigue. At this point, the patient is assessed for current disease and treatment status, a review of body systems, and an in-depth fatigue evaluation. In addition, the patient is assessed for the presence of seven treatable factors known to contribute to fatigue: pain, emotional distress, sleep disturbance, anemia, alteration in nutrition, deconditioning, and comorbidities. If any of these conditions are present, they should be treated according to practice guidelines, with referral to other care professionals as appropriate, and the patient's fatigue should be re-evaluated regularly. If none of the seven factors are present or if the fatigue is unresolved, selection of appropriate fatigue management and treatment strategies is done within the context of the patient's clinical status: (ie, receiving active cancer treatment, disease-free long-term follow-up, or care at the end of life). Management of fatigue is cause-specific when conditions known to cause fatigue (such as infection, fluid and electrolyte imbalances, or cardiac dysfunction) can be identified and treated. When

specific causes of fatigue cannot be identified and corrected, nonpharmacologic and pharmacologic treatment of the fatigue should still be done.

Nonpharmacologic interventions may include a moderate exercise program to improve functional capacity and activity tolerance, psychosocial programs to manage stress and increase support, attention-restoring therapies to decrease cognitive alterations and improve mood state, energy conservation to maintain energy, and nutritional and sleep interventions for patients with disturbances in eating or sleeping. Pharmacologic therapy may include drugs, such as antidepressants for depression or erythropoietin for anemia. A few clinical reports of the use of psychostimulants suggest the need for further research on these agents as potential treatment modalities in managing fatigue.

Effective management of cancer-related fatigue involves an informed and supportive oncology care team that assesses patients' fatigue levels regularly, counsels and educates patients regarding strategies for coping with fatigue,<sup>194</sup> and uses institutional experts for referral of patients with unresolved fatigue.<sup>43</sup>

#### **Disclosures for the NCCN Cancer-Related Fatigue Guidelines Panel**

At the beginning of each panel meeting to develop NCCN guidelines, panel members disclosed financial support they have received in the form of research support, advisory committee membership, or speakers' bureau participation. Some Members of the panel indicated that they have received support from the following: Amgen, Cephalon, Forest Laboratories, Inc., and Ortho Biotech. Some panel members do not accept any support from industry. The panel did not regard any potential conflicts of interest as sufficient reason to disallow participation in panel deliberations by any member.

## Appendix

### Fatigue Measurement

#### *A resource to facilitate selection of instruments to measure fatigue*

Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. *The Lancet* 2003;262:640-650.

*(This resource provides a detailed description of six scales frequently used in cancer patients to measure fatigue.)*

Jacobsen PB. Assessment of fatigue in cancer patients. *J Natl Cancer Inst Monogr* 2004; 32: 93-97.  
*(Includes factors to consider in selecting a fatigue measure.)*

Meek PM, Nail LM, Barsevick A, et al. Psychometric testing of fatigue instruments for use with cancer patients. *Nurs Res* 2000;49:181-190.

*(Study evaluates psychometric properties of several commonly used fatigue measures.)*

National Cancer Institute. Fatigue (PDQ) Health Professional Version (11/18/05). Retrieved from <http://www.nci.nih.gov/cancertopics/pdq/supportivecare/fatigue/healthprofessional/>

*(Gives citation links to nine commonly used scales to measure fatigue.)*

Oncology Nursing Society. Measuring oncology nursing-sensitive patient outcomes: Fatigue evidence-based summary (June 22, 2004). Retrieved from

<http://onsopcontent.ons.org/toolkits/evidence/Clinical/Summaries.shtml>

*(Provides two detailed tables summarizing scale descriptions and psychometric properties for 13 scales.)*

Piper BF. Measuring fatigue. In: Frank-Stromborg M, Olsen SJ, eds. *Instruments for clinical health-care research*. 3rd ed. Boston, Ma: Jones & Bartlett. 2004:538-553.

*(Provides four detailed tables that summarize scale descriptions and psychometric properties for all fatigue scales that have been developed to date including single item and multiple item, single dimension scales and multidimensional scales.)*

Wu HS, McSweeney M. Measurement of fatigue in people with cancer. *Oncol Nurs Forum* 2001;28:1371-1384.

*(Qualitative review of commonly used fatigue measures.)*

## References

1. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. *The Lancet* 2003;262:640-650.
2. Irvine D, Vincent L, Graydon JE, et al. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy: A comparison with the fatigue experienced by healthy individuals. *Cancer Nurs* 1994;17:367-378.
3. Dean GE, Spears L, Ferrell BR, et al. Fatigue in patients with cancer receiving interferon alpha. *Cancer Pract* 1995;3:164-172.
4. Longman AJ, Braden CJ, Mishel MH. Side effects burden in women with breast cancer. *Cancer Pract* 1996;4:274-280.
5. Cella D. The functional assessment of cancer therapy-anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. *Semin Hematol* 1997;34[suppl 2]:13-19.
6. Sitzia J, Huggins L. Side effects of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy for breast cancer. *Cancer Pract* 1998;6:13-21.
7. Hann DM, Garovoy N, Finkelstein B. Fatigue and quality of life in breast cancer patients undergoing autologous stem cell transplantation: A longitudinal comparative study. *J Pain Symptom Manage* 1999;17:311-319.
8. Jacobsen PB, Hann DM, Azzarello LM, et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: Characteristics, course, and correlates. *J Pain Symptom Manage* 1999;18:233-242.
9. Collins JJ, Devine TD, Dick GS, et al. The measurement of symptoms of young children with cancer: The validation of the Memorial Assessment Scale in children aged 7-12. *J Pain Symptom Manage* 2002;23:10-16.
10. Wagner LI and Cella D. Fatigue and cancer: causes, prevalence, and treatment approaches. *Br J Cancer* 2004;91:822-828.
11. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. *Oncologist* 2007;12 Suppl 1:4-10.
12. Andrykowski MA, Curran SL, Lightner R. Off-treatment fatigue in breast cancer survivors: A controlled comparison. *J Behav Med* 1998;21:1-18.
13. Broeckel JA, Jacobsen PB, Horton J, et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. *J Clin Oncol* 1998;16:1689-1696.
14. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. *J Clin Oncol* 2000;18:743-753.
15. Crom DB, Hinds PS, Gattuso JS, et al. Female survivors of Hodgkin's disease: Self-care practices and perceived vulnerability to breast cancer. *Oncol Nurs Forum* 2005;32:1131-41.
16. Bower JE, Ganz PA, Aziz N, et al. T-cell homeostasis in breast cancer survivors with persistent fatigue. *J Natl Cancer Inst* 2003;95:1165-1168.
17. Fossa SD, Dahl AA, Loge JH. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. *J Clin Oncol* 2003;21:1249-1254.
18. Haghghat S, Akbari ME, Holakouei K, et al. Factors predicting fatigue in breast cancer patients. *Support Care Cancer* 2003;11:533-538.
19. Ruffer JU, Flechtner H, Tralis P, et al. Fatigue in long-term survivors of Hodgkin's lymphoma: A report from the German Hodgkin Lymphoma Study Group. *Eur J Cancer* 2003;39:2179-2186.

20. Servaes P, Verhagen S, Bleijenberg G. Determinants of chronic fatigue in disease-free breast cancer patients: A cross-sectional study. *Ann Oncol* 2002;13:589-598.
21. Servaes P, Verhagen S, Schreuder HW, et al. Fatigue after treatment for malignant and benign bone and soft tissue tumors. *J Pain Symptom Manage* 2003;26:1113-1122.
22. Olson K. A new way of thinking about fatigue: a reconceptualization. *Oncol Nurs Forum*. Jan 2007;34:93-99.
23. Olson K, Krawchuk A, Quddusi T. Fatigue in individuals with advanced cancer in active treatment and palliative settings. *Cancer Nurs*. 2007;30:E1-E10.
24. Vogelzang N, Breitbart W, Cella D, et al. The Fatigue Coalition. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tri-part assessment survey. *Semin Hematol* 1997;34[suppl 2]:4-12.
25. Hinds PS, Quargnenti A, Bush AJ, et al. An evaluation of the impact of a self-care coping intervention on psychological and clinical outcomes in adolescents with newly diagnosed cancer. *Eur J Oncol Nurs* 2000;4:6-17.
26. Janda M, Gerstner N, Obermair A, et al. Quality of life changes during conformal radiation therapy for prostate carcinoma. *Cancer* 2000;89:1322-1328.
27. Nail LM, Jones LS. Fatigue as a side effect of cancer treatment: Impact on quality of life. *Qual Life Nurs Challenge* 1995;4:8-13.
28. Ferrell BR, Grant M, Dean GE, et al. Bone tired: The experience of fatigue and its impact on quality of life. *Oncol Nurs Forum* 1996;23:1539-1547.
29. Morrow GR, Andrews PLR, Hickok JT, et al. Fatigue associated with cancer and its treatment. *Support Care Cancer* 2002;10:389-398.
30. Wood LJ, Nail LM, Gister A, et al. Cancer chemotherapy-related symptoms: Evidence to suggest a role for proinflammatory cytokines. *Oncol Nurs Forum* 2006;33:535-543.
31. Von Hoff DD. Asthenia: Incidence, etiology, pathophysiology, and treatment. *Sel Cancer Ther* 1998;1:184-197.
32. Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR. Mechanisms of cancer-related fatigue. *Oncologist*. 2007;12 Suppl 1:22-34.
33. Mock V, Atkinson A, Barsevick A, et al (Chair + 18 member panel). NCCN practice guidelines for cancer-related fatigue. *Oncology* 2000;14:151-161.
34. Mock V, Atkinson A, Barsevick A, et al. NCCN (v.1.2003) Cancer-related fatigue NCCN Clinical Practice Guidelines in Oncology. *JNCCN* 2003;1:308-331.
35. Stone P, Hardy J, Broadley K, et al. Fatigue in advanced cancer: A prospective controlled cross-sectional study. *Br J Cancer* 1999;79:1479-1486.
36. Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. *Support Care Cancer* 1996;4:82-96.
37. Given CW, Given B, Azzouz F, et al. Comparison of changes in physical functioning of elderly patients with new diagnoses of cancer. *Med Care* 2000;38:482-493.
38. Hinds PS, Hockenberry-Eaton M, Gilger E, et al. Comparing patient, parent and staff descriptions in fatigue in pediatric patients. *Cancer Nurs* 1999;22:277-288.
39. Given B, Given CW, McCorkle R, et al. Pain and fatigue management: results of a nursing randomized clinical trial. *Oncol Nurs Forum* 2002;29:949-956.

40. Mock V, McCorkle R, Ropka ME, et al. Fatigue and physical functioning during breast cancer treatment. *Oncol Nurs Forum* 2002;29:338.
41. Nail LM. Fatigue in patients with cancer. *Oncol Nurs Forum* 2002;29:537-544.
42. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. *Cancer* 2001;Suppl(92/6):1664-1668.
43. Escalante CP, Grover T, Johnson BA, et al. A fatigue clinic in a comprehensive cancer center. *Cancer* 2001;(Suppl 1):1708-1713.
44. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. *Cancer* 1999;85:1186-1196.
45. Piper BF, Dodd MJ, Ream E, et al. Improving the clinical measurement of cancer treatment-related fatigue. In: *Better Health Through Nursing Research: International State of the Science*. Washington, DC: American Nurses Association 1999:99.
46. Hockenberry MJ, Hinds PS, Barrera P, et al. Three instruments to assess fatigue in children with cancer: The child, parent, and staff perspectives. *J Pain Symptom Manage* 2003;25:319-328.
47. Varni JW, Burwinkle TM, Katz ER, et al. The PedsQL in pediatric cancer: Reliability and validity of the Pediatric Quality of Life inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. *Cancer* 2002;94:2090-2106.
48. Hinds PS, Hockenberry M, Tong X, et al. Cancer related fatigue in adolescents: Developing and testing a self-report fatigue instrument. *Journal of Pain and Symptom Management*, in press.
49. Grant M. Fatigue and quality of life with cancer. In: *Winningham ML, Barton-Burke M, eds. Fatigue in Cancer: A Multidimensional Approach*. Sudbury: Jones & Bartlett 2000:353-364.
50. Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. *Oncology* 1998;12:369-377.
51. Curt G, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: New finding from the fatigue coalition. *Oncologist* 2000;5:353-360.
52. Barsevick AM, Whitmer K, Walker L. In their own words: using the common sense model to analyze patient descriptions of cancer-related fatigue. *Oncol Nurs Forum* 2001;28:1363-1369.
53. Holley S. Cancer-related fatigue: Suffering a different fatigue. *Cancer Pract* 2000;8:87-95.
54. Cleeland CS, Wang XS. Measuring and understanding fatigue. *Oncology* 1999;13:91-97.
55. Portenoy RK, Itri LM. Cancer-related fatigue: Guidelines for evaluation and management. *Oncologist* 1999;4:1-10.
56. Berger AM, Walker SN. An explanatory model of fatigue in women receiving adjuvant breast cancer chemotherapy. *Nurs Res* 2001;50:42-52.
57. Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. *Oncol Nurs Forum* 2001;28:465-470.
58. Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: a review. *Eur J Cancer Care* 2001;10:245-255.
59. Hinds PS, Hockenberry M, Rai SN, et al. Nocturnal sleep interruptions, sleep quality and fatigue in hospitalized children with cancer. *Oncology Nursing Forum*, in press.
60. Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. *J Clin Oncol* 2000;18:893-903.
61. Newell S, Sanson-Fisher RW, Girgis A, et al. The physical and psycho-social experiences of patients attending an outpatient medical oncology department: a cross-sectional study. *Eur J Cancer Care (Engl)* 1999;8:73-82.



62. Loge JH, Abrahamsen AF, Ekeberg, et al. Fatigue and psychiatric morbidity among Hodgkin's disease survivors. *J Pain Symptom Manage* 2000;19:91-99.
63. Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? *Support Care Cancer* 1998;6:101-108.
64. Savard J, Morin CM. Insomnia in the context of cancer: A review of a neglected problem. *J Clin Oncol* 2001;19:895-908.
65. Berger, A. & Mitchell, S. Modifying Cancer-Related Fatigue by optimizing sleep quality. *JNCCN (in press)*
66. Roscoe JA, Kaufman ME, Matteson-Rusby SE, et al. Cancer-related fatigue and sleep disorders. *Oncologist*. 2007;12 Suppl 1:35-42.
67. Berger AM, Parker KP, Young-McCaughan S, et al. Sleep wake disturbances in people with cancer and their caregivers: state of the science. *Oncol Nurs Forum* 2005;32:E98-126.
68. Berger AM, Farr L. The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. *Oncol Nurs Forum* 1999;26:1663-1671.
69. Berger AM. Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. *Oncol Nursing Forum* 1998;25:51-62.
70. Palesh OG, Collie K, Batiuchok D, et al. A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. *Biol Psychol*. Apr 2007;75(1):37-44.
71. Mock V, Frangakis C, Davidson N, et al. Exercise manages fatigue during breast cancer treatment: A RCT. *Psycho-Oncol*, 2005;14:464-477.
72. Dimeo FC, Stieglitz RD, Novelli-Fischer U, et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. *Cancer* 1999;85:2273-2277.
73. Schwartz AL. Daily fatigue patterns and effect of exercise in women with breast cancer. *Cancer Pract* 2000;8:16-24.
74. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. *Arch Intern Med* 2000;160:526-534.
75. Strasser F, Palmer JL, Schover LR, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. *Cancer* 2006;107:2949-2957.
76. Mitchell SA, Beck SL, Hood LE, et al. Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. *Clinical Journal of Oncology Nursing* 2007;11:99-113.
77. Barsevick AM, Whitmer K, Sweeney C, et al. A pilot study examining energy conservation for cancer treatment-related fatigue. *Cancer Nurs* 2002;25:333-341.
78. Richardson A, Ream E, Wilson-Barnett J. Fatigue in patients receiving chemotherapy: Patterns of change. *Cancer Nurs* 1998;21:17-30.
79. Barsevick A, Dudley W, Beck S, et al. A randomized clinical trial of energy conservation for cancer-related fatigue. *Cancer* 2004;100:1302-1310.
80. Graydon JE, Bubela N, Irvine D, et al. Fatigue-reducing strategies used by patients receiving treatment for cancer. *Cancer Nurs* 1995;18:23-28.
81. Richardson A, Ream EK. Self-care behaviours initiated by chemotherapy patients in response to fatigue. *Int J Nurs Stud* 1997;34:35-43.
82. Mustian KM, Morrow GR, Carroll JK, Figueroa-Moseley CD, Jean-Pierre P, Williams GC. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. *Oncologist*. 2007;12 Suppl 1:52-67.

83. American College of Sports Medicine. ACSM's exercise management for person with chronic diseases and disabilities. Champaign, IL: Human Kinetics, 2005.
84. Courneya KS, Friedenreich CM, Sela RA, et al. The group psychotherapy and home-based physical exercise (group-hope) trial in cancer survivors: physical fitness and quality of life outcomes. *Psychooncology* 2003b;12:357-374.
85. Courneya KS, Mackey JR, Bell GJ, et al. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. *J Clin Oncol* 2003;21:1660-1668.
86. Mock V, Cameron L, Tompkins C, et al. Every Step Counts: A Walking Exercise Program for Persons Living with Cancer. Baltimore: Johns Hopkins University, 1997.
87. Schmitz KH, Holtzman J, Courneya KS, et al. Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2005;14:1588-1595.
88. Stevinson C, Lawlor DA, Fox, KR. Exercise interventions for cancer patients: systematic review of controlled trials. *Cancer Causes Control* 2004;15:1035-1056.
89. Conn VS, Hafdahl AR, Porock DC, et al. A meta-analysis of exer interventions among people treated for cancer. *Supportive Care in Cancer* 2006;14:699-712.
90. McNeely ML, Campbell KL, Rowe BH et al. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. *CMAJ* 2006 4;175:34-41.
91. Stricker CT, Drake D, Hoyer KA, Mock V. Evidence-based practice for fatigue management in adults with cancer: exercise as an intervention. *Oncol Nurs Forum* 2004;31:963-976.
92. Douglas E. Exercise in cancer patients. *Physical Therapy Reviews* 2005;10:71-88.
93. Knols R, Aaronson NK, Uebelhart D, et al. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. *J Clin Oncol* 2005;23:3830-3842.
94. Visovsky C, Dvorak C. Exercise and cancer recovery. *J of Issues in Nursing* 2005;10:1-15.
95. Galvao DA and Newton RU. Review of exercise intervention studies in cancer patients. *J Clin Oncol* 2005;23:899-909.
96. MacVicar SB, Winningham ML. Promoting the functional capacity of cancer patients. *Cancer Bull* 1986;38:235-239.
97. Drouin JS, Armstrong H, Krause S, et al. Effects of aerobic exercise training on peak aerobic capacity, fatigue, and psychological factors during radiation for breast cancer. *Rehab Oncol* 2005;23:11-17.
98. Dimeo FC, Tilmann MHM, Bertz H, et al. Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. *Cancer* 1997;79:1717-1722.
99. Schwartz AL, Mori M, Gao R, et al. Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. *Med Sci Sports Exerc* 2001;33:718-723.
100. Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. *J Clin Oncol* 2003;21:1653-1659.
101. Dimeo F, Fetscher S, Lange W, et al. Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. *Blood* 1997;90:3390-3394.
102. Segal R, Evans W, Johnson D. Structured exercise improves physical functioning in women with stages I and II breast cancer: Results of randomized controlled trial. *J Clin Oncol* 2001;19:657-665.

103. Schwartz AL. Fatigue mediates the effect of exercise on quality of life. *Qual Life Res* 1999;8:529-538.
104. Stark D, Kiely M, Smith A, et al. Anxiety disorders in cancer patients: Their nature, associations, and relation to quality of life. *J Clin Oncol* 2002;20:3137-3148.
105. Beck SL, Dudley WN, Barsevick A. Pain, sleep disturbance, and fatigue in patients with cancer: Using a mediation model to test a symptom cluster. *Oncol Nurs Forum* (Online Exclusive) 2005;32:E48-E55.
106. Fawzy NW. A psychoeducational nursing intervention to enhance coping and affective state in newly diagnosed malignant melanoma patients. *Cancer Nurs* 1995;18:427-438.
107. Fawzy FI, Cousins N, Fawzy NW, et al. A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. *Arch Gen Psychiatry* 1990;47:720-725.
108. Spiegel D, Bloom JR, Yalom ID. Group support for metastatic cancer patients: A randomized prospective outcome study. *Arch Gen Psychiatry* 1981;38:527-533.
109. Ream E, Richardson A, and Alexander-Dann C. Supportive intervention for fatigue in patients undergoing chemotherapy: a randomized controlled trial. *J Pain Symptom Manage* 2006;31:148-61
110. Yates P, Aranda S, Hargraves M, et al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant women receiving adjuvant chemotherapy for early-stage breast cancer. *J Clin Oncol* 2005;23:6027-36.
111. Kim Y, Roscoe JA, Morrow GR. The effects of information and negative affect on severity of side effects from radiation therapy for prostate cancer. *Support Care Cancer* 2002;10:416-21.
112. Forester B, Kornfeld DS, Fleiss JL. Psychotherapy during radiotherapy: Effects on emotional and physical distress. *Am J Psychiatry* 1985;142:22-27.
113. Gaston-Johansson F, Fall-Dickson JM, Nanda J, et al. The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation. *Cancer Nurs* 2000;23:277-285.
114. Jacobsen PB, Meade CD, Stein KD, et al. Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. *J Clin Oncol* 2002;20:2851-2862.
115. Cimprich B. Attentional fatigue following breast cancer surgery. *Res Nurs Health* 1992;15:199-207.
116. Cimprich B, Ronis DL. An environmental intervention to restore attention in women with newly diagnosed breast cancer. *Cancer Nurs* 2003;26:284-294.
117. Cimprich B. Development of an intervention to restore attention in cancer patients. *Cancer Nurs* 1993;16:83-92.
118. Cimprich B, So H, Ronis DL, et al. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. *Psychooncology* 2005;14:70-78.
119. Brown JK. A systematic review of the evidence on symptom management of cancer-related anorexia and cachexia. *Oncol Nurs Forum* 2002;29:517-532.
120. Owen DC, Parker KP, McGuire DB. Comparison of subjective sleep quality in patients with cancer and healthy subjects. *Oncol Nurs Forum* 1999;26:1649-1651.
121. Page, M, Berger A, Johnson L. Putting evidence into practice (PEP): Evidence-based interventions for sleep-wake disturbances. *Clin J of Oncol Nurs* 2006;10:753-767.
122. Berger AM, VonEssen S, Khun BR, et al. Feasibility of a sleep intervention during adjuvant breast cancer chemotherapy. *Oncol Nurs Forum*. 2002;29:1431-1441.
123. Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to

breast cancer, Part I: Sleep and psychological effects. *J Clin Oncol* 2005;23:6083-6096.

124. Davidson JR, Waisberg JL, Brundage MD et al. Nonpharmacologic group treatment of insomnia: a preliminary study with cancer survivors. *Psychooncology* 2001;10:389-97.

125. Quesnel C, Savard J, Simard S, et al. Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. *J Consult Clin Psychol* 2003;71:189-200.

126. Levesque M, Savard J, Simard S, et al. Efficacy of cognitive therapy for depression among women with metastatic cancer: a single-case experimental study. *J Behav Ther Exp Psychiatry* 2004;35:287-305.

127. Cassileth BR, Vickers AJ. Massage therapy for symptom control: outcome study at a major cancer center. *J Pain Symptom Manage* 2004;28:244-9.

128. Post-White J, Kinney ME, Savik K, et al. Therapeutic massage and healing touch improve symptoms in cancer. *Integr Cancer Ther* 2003;2:332-44.

129. Ahles TA, Tope DM, Pinkson B, et al. Massage therapy for patients undergoing autologous bone marrow transplantation. *J Pain Symptom Manage*.1999;18:157-163

130. Cohen L, Warneke C, Fouladi RT, et al. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. *Cancer* 2004;100:2253-60.

131. Kim SD and Kim HS. Effects of a relaxation breathing exercise on fatigue in haemopoietic stem cell transplantation patients. *J Clin Nurs* 2005;14:51-55.

132. Kim SD and Kim HS. Effects of a relaxation breathing exercise on anxiety, depression, and leukocyte in hemopoietic stem cell transplantation patients. *Cancer Nurs* 2005;28:79-83.

133. Cannici J, Malcolm R and Peek LA. Treatment of insomnia in cancer patients using muscle relaxation training. *J Behav Ther Exp Psychiatry* 1983;14:251-6.

134. Decker TW, Cline-Elsen J, Gallagher M. Relaxation therapy as an advunct in radiation oncology. *J Clin Psychol*. 1999;48:388-93.

135. Shapiro SL, Bootzin RR, Figueredo AJ, et al. The efficacy of mindfulness-based stress reduction in the treatment of sleep disturbance in women with breast cancer: an exploratory study. *J Psychosom Res* 2003;54:85-91.

136. Carlson LE, Speca M, Patel KD, et al. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. *Psychosom Med* 2003;65:571-81.

137. Carlson LE, Speca M, Patel KD, et al. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. *Psychoneuroendocrinology* 2004;29:448-74.

138. Carlson LE and Garland SN. Impact of mindfulness-based stress reduction (MBSR) on sleep, mood, stress and fatigue symptoms in cancer outpatients. *Int J Behav Med* 2005;12:278-85.

139. Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR. Pharmacologic treatment of cancer-related fatigue. *Oncologist*. 2007;12 Suppl 1:43-51.

140. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. *J Clin Oncol* 2003;21:4635-4641.

141. Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. *Breast Cancer Res Treat* 2005;89:243-249.

142. Breitbart W, Rosenfeld B, Kaim M, et al. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. *Arch Intern Med* 2001;161:411-420.
143. Razon M, Dreisbach A, Lertora JJJ, et al. Palliative uses of methylphenidate in patients with cancer: A review. *J Clin Oncol* 2002;20:335-339.
144. Bruera E, Driver L, Valero V, et al. Patient controlled methylphenidate for cancer related fatigue: A randomized controlled trial. ASCO Annual Meeting 2005, Abstract 8045.
145. Lower E, Fleishman S, Cooper A, et al. A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and “chemobrain” in adult cancer patients. ASCO Annual Meeting 2005, Abstract 8000.
146. Caraceni A, Simonetti F. Psychostimulants: new concepts for palliative care from the modafinil experience. *J Pain Symptom Manage* 2004;28:97-9.
147. Cox JM, Pappagallo M. Modafinil: A gift to portmanteau. *Am J Hosp Palliat Care* 2001;18:408-410.
148. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2006. *CA Cancer J Clin* 2006;56:106-130.
149. Jacobsen PB, Stein K. Is fatigue a long-term side effect of breast cancer treatment? *Cancer Control* 1999;6:256-263.
150. Knobel H, Loge JH, Nordoy T, et al. High level of fatigue in lymphoma patients treated with high dose therapy. *J Pain Symptom Manage* 2000;19:446-456.
151. Bower JE, Ganz PA, Aziz N, et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. *Psychosom Med* 2002;64:604-611.
152. Cella D, Davis K, Breitbart W, et al. Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. *J Clin Oncol* 2001;19:3385-3391.
153. Knobel H, Loge JH, Lund MB, et al. Late medical complications and fatigue in Hodgkin’s Disease survivors. *J Clin Oncol* 2001;19:3226-3233.
154. Stewart DE, Wong F, Duff S, et al. What doesn’t kill you makes you stronger: An ovarian cancer survivor study. *Gynecologic Oncol* 2001;83:537-542.
155. Servaes P, Prins J, Verhagen S, et al. Fatigue after breast cancer and in chronic fatigue syndrome: Similarities and differences. *J Psychosom Res* 2002;52:453-459.
156. Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey. *Ann Oncol* 2000;11:971-975.
157. Woo B, Dibble SL, Piper BF, et al. Differences in fatigue by treatment methods in women with breast cancer. *Oncol Nurs Forum* 1998;25:915-920.
158. Hann DM, Jacobsen PB, Martin SC, et al. Fatigue in women treated with bone marrow transplantation for breast cancer: a comparison with women with no history of cancer. *Support Care Cancer* 1997;5:44-52.
159. Gielissen MF, Verhagen S, Witjes F, Bleijenberg G. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. *J Clin Oncol*. Oct 20 2006;24(30):4882-4887.
160. Geinitz H, Zimmermann FB, Thamm R, et al. Fatigue in patients with adjuvant radiation therapy for breast cancer: long-term follow-up. *J Cancer Res Clin Oncol* 2004;130:327-333.
161. Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R. Effects of supervised exercise training on cardiopulmonary function and

fatigue in breast cancer survivors during and after treatment. *Cancer* 2007;110:918-925.

162. Vallance JK, Courneya KS, Plotnikoff RC, Yasui Y, Mackey JR. Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. *J Clin Oncol*. 2007;25:2352-2359.

163. Loge JH, Ekeberg O, Kaasa S. Fatigue in the general Norwegian population: Normative data and associations. *J Psychosom Res* 1998;45:53-65.

164. Segar ML, Katch VL, Roth RS, et al. The effect of aerobic exercise on self-esteem and depressive and anxiety symptoms among breast cancer survivors. *Oncol Nurs Forum* 1998;25:107-113.

165. Oldervoll LM, Kaasa S, Knobel H, et al. Exercise reduces fatigue in chronic fatigued Hodgkins disease survivors--results from a pilot study. *Eur J Cancer* 2003;39:57-63.

166. Berger AM, VonEssen S, Kuhn BR, et al. Adherence, sleep, and fatigue outcomes after adjuvant breast cancer chemotherapy: results of a feasibility intervention study. *Oncol Nurs Forum* 2003;30:513-522.

167. Yennurajalingam S, Bruera E. Palliative management of fatigue at the close of life: "it feels like my body is just worn out". *JAMA* 2007;297:295-304.

168. Lundh Hagelin C, Seiger A, Furst CJ. Quality of life in terminal care--with special reference to age, gender and marital status. *Supportive Care in Cancer* 2006;14:320-328.

169. Peters L, Sellick K. Quality of life of cancer patients receiving inpatient and home-based palliative care. *Journal of Advanced Nursing* 2006;53:524-533.

170. Walsh D, Rybicki L. Symptom clustering in advanced cancer. *Supportive Care in Cancer* 2006;14:831-836.

171. Mystakidou K, Parpa E, Katsouda E, Galanos A, Vlahos L. The role of physical and psychological symptoms in desire for death: a

study of terminally ill cancer patients. *Psycho-Oncology* 2006;15:355-360.

172. Wong RK Franssen E, Szumacher E, et al. What do patients living with advanced cancer and their carers want to know? A needs assessment. *Support Care Cancer* 2002;10:408-415.

173. Harris KA. The informational needs of patients with cancer and their families. *Cancer Pract* 1998;6:39-46.

174. Rose KE. A qualitative analysis of the information needs of informal carers of terminally ill cancer patients. *J Clin Nurs* 1999;8:81-88.

175. Krishnasamy M. Fatigue in advanced cancer: Meaning before measurement? *Int J Nurs Stud* 2000;37:401-414.

176. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. *Support Care Cancer* 2000;8:175-179.

177. Wolfe J, Grier HE, Klar N, et al. Symptoms and suffering at the end of life in children with cancer. *N Engl J Med* 2000;342:326-333.

178. Given B, Given C, Azzouz F, et al. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. *Nurs Res* 2001;50:222-232

179. Oldervoll LM, Loge JH, Paltiel H, et al. The effect of a physical exercise program in palliative care: A phase II study. *Journal of Pain & Symptom Management* 2006;31:421-430.

180. Porock D, Kristjanson LJ, Tinnelly K, et al. An exercise intervention for advanced cancer patients experiencing fatigue: A pilot study. *J Palliat Care* 2000;16:30-36.

181. Strong A, Karavatas G, Reicherter EA. Recommended exercise protocol to decrease cancer-related fatigue and muscle wasting in patients with multiple myeloma. *Topics in Geriatric Rehabilitation* 2006;22:172-186.

182. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. *Journal of Clinical Oncology* 2006;24:2073-2078.
183. Hanna A, Sledge G, Mayer ML, et al. A phase II study of methylphenidate for the treatment of fatigue. *Supportive Care in Cancer* 2006;14:210-215.
184. Sarhill N, Walsh D, Nelson KA, Homs J, LeGrand S, Davis MP. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. *Am J Hosp Palliat Care* 2001;18:187-192.
185. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. *Arch Intern Med* 2001;161:411-420.
186. Lundstrom SH, Furst CJ. The use of corticosteroids in Swedish palliative care. *Acta Oncologica*. 2006;45:430-437.
187. Morrow GR, Ryan JL, Kohli S, et al. Modafinil (Provigil<sup>®</sup>) for persistent post-treatment fatigue: An open label study of 82 women with breast cancer. *MASCC international symposia 2006*, Abstract 11-070.
188. Kaleita T, Cloughesy J, Ford W, et al. A pilot study of modafinil (Provigil) for treatment of fatigue and neurobehavioral dysfunction in adult brain tumor patients. *Ninth Annual Meeting of the Society for Neuro-Oncology 2004*, Abstract QL-06.
189. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. *J Clin Oncol* 1993;11:762-767.
190. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. *J Clin Oncol*. Oct 1999;17:3299-3306.
191. Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. *J Pain Symptom Manage* 2004;27:360-369.
192. Cruciani RA, Dvorkin E, Homel P et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. *Ann N Y Acad Sci*. 2004;1033:168-76.
193. Cruciani RA, Dvorkin E, Homel P, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. *J Pain Symptom Manage* 2006;32:551-559.
194. Johnson JE. Self-regulation theory and coping with physical illness. *Res Nurs Health* 1999;22:435-448.

Manuscript  
update in  
progress